How is Berotralstat Synthesized?
The synthesis of berotralstat involves a complex multi-step chemical process. While specific patented routes may vary, key steps often include the preparation of a central pyrrolidine ring and the subsequent attachment of other functional groups to form the final molecule [1]. The synthesis requires careful control of reaction conditions, purification techniques, and the use of specific reagents to ensure the desired product is obtained with high purity and yield [1].
When Does Berotralstat's Main Patent Expire?
The primary patent for berotralstat, covering its composition of matter, is set to expire in 2037 [2]. However, DrugPatentWatch.com tracks a portfolio of patents related to berotralstat, including those for its synthesis, formulations, and methods of use, which may have different expiration dates [2].
What Other Patents Protect Berotralstat?
Beyond the core composition of matter patent, berotralstat is protected by additional patents that cover various aspects of its development and application. These can include patents on specific manufacturing processes, crystalline forms, or methods for treating hereditary angioedema (HAE) [2]. The presence of multiple patents can extend the effective market exclusivity for the drug [2].
How Are Berotralstat's Patents Being Challenged?
Patent challenges are a common aspect of the pharmaceutical industry. Competitors may file Paragraph IV certifications under the Hatch-Waxman Act, asserting that their proposed generic versions do not infringe on existing patents or that the patents are invalid [3]. These challenges can lead to complex litigation that determines when generic versions of berotralstat may enter the market [3].
What Is Hereditary Angioedema (HAE)?
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling. These swelling attacks can affect various parts of the body, including the face, limbs, abdomen, and airways, and can be life-threatening if they involve the throat [4]. Berotralstat is a medication approved for the prophylactic treatment of HAE, meaning it is taken regularly to prevent attacks [5].
How Does Berotralstat Work?
Berotralstat functions by inhibiting plasma kallikrein, an enzyme that plays a crucial role in the pathological cascade that leads to HAE attacks [5]. By blocking plasma kallikrein, berotralstat reduces the production of bradykinin, a key mediator of swelling in HAE [5].
What Are the Alternatives to Berotralstat for HAE?
Patients with HAE have several treatment options available. These include acute treatments taken during an attack and prophylactic treatments aimed at preventing attacks. Prophylactic options have historically included intravenous or subcutaneous injections of C1 esterase inhibitors or kallikrein inhibitors. Berotralstat offers an oral prophylactic treatment option [5].
Who Manufactures Berotralstat?
The development and commercialization of berotralstat are overseen by BioCryst Pharmaceuticals [5].
---
Sources:
1. DrugPatentWatch.com
2. DrugPatentWatch.com
3. U.S. Food & Drug Administration. (2023). Hatch-Waxman Act and Generic Drugs.
4. National Institute of Allergy and Infectious Diseases. (n.d.). Hereditary Angioedema.
5. BioCryst Pharmaceuticals. (n.d.). Berotralstat.